Deutsche Bank Downgrades ResMed (RMD) to Hold
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/16/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- S&P 500 ends lower as investors weigh data, Middle East tensions
- SanDisk upgraded at JPMorgan after investor day; shares climb
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
JPMorgan Downgrades ResMed (RMD:AU) (RMD) to Underweight
January 25, 2019 7:10 AM ESTJPMorgan analyst David Low downgraded ResMed (RMD:AU) (NYSE: RMD) from Neutral to Underweight with a price target of AUD13.40.
Low notes results were boosted by a one-off benefit. Sales will likely be subdued over much of 2019 as the business cycles... More
Goldman Sachs Downgrades ResMed (RMD:AU) (RMD) to Neutral
January 25, 2019 7:01 AM ESTGoldman Sachs analyst Chris Cooper downgraded ResMed (RMD:AU) (NYSE: RMD) from Buy to Neutral with a price target of AUD15.20 (from AUD16.70).
Cooper said shares were priced for perfection going into the 2Q print and the company delivered a meaningful 3% sales... More
ResMed (RMD) Tops Q2 EPS by 5c, Revenues Miss
January 24, 2019 4:09 PM ESTResMed (NYSE: RMD) reported Q2 EPS of $1.00, $0.05 better than the analyst estimate of $0.95. Revenue for the quarter came in at $651.1 million versus the consensus estimate of $672.91 million.
Revenue increased 8% to $651.1 million; up 9% on a constant currency basisGross Margin expanded 70bps to... More